WebApr 9, 2024 · BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic … WebBusiness Wire. BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and ...
Our Company - BELLUS Health Inc.
WebBELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity … Webbellus health is a drug development company and our product candidates are not yet commercialized. INVESTING IN OUR COMMON SHARES INVOLVES A SIGNIFICANT … top false eyelashes brands
BELLUS Health Inc.: Corporate Presentation – November 2024
WebApr 3, 2024 · Obtenez le cours le plus récent de BELLUS Health Inc. (BLU), ainsi que les nouvelles, les opérations, les graphiques, les activités d’initiés et les recommandations … WebApr 12, 2024 · 3 brokerages have issued 12 month price objectives for BELLUS Health's shares. Their BLU share price forecasts range from $20.00 to $21.00. On average, they predict the company's share price to reach $20.67 in the next year. This suggests a possible upside of 203.9% from the stock's current price. View analysts price targets for BLU or … WebDec 13, 2024 · Shares of Bellus Health ( BLU -1.69%), a clinical-stage biotechnology company, are soaring in response to positive clinical-trial data. Investors excited about the company's lead candidate BLU ... picture of beets vegetable